Australia Pharmaceuticals News

Related Pharmaceuticals Industry News

• April 2023: Aurobindo Pharma approved the transfer of two API units (Unit V and XVII) to its wholly-owned subsidiary Apitoria Pharma Private Limited.
• January 2023: Novartis sold its active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, to Sterling Pharma Solutions. Under the terms of the agreement, Novartis continues to manufacture several APIs for cardiovascular, immunology, and oncology medicines at Ringaskiddy.

• January 2023: Elicio Therapeutics engineers lymph node-targeted adjuvants and vaccines for an array of aggressive cancers and infectious diseases and entered into a definitive merger agreement with Angion Biomedica Corp to focus on advancing Elicio's proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
• November 2022: Hubro Therapeutics AS acquired GM-CSF vaccine adjuvant from Targovax ASA in an asset purchase agreement for a cash payment of NOK10 million. Hubro continues the development of GM-CSF as an adjuvant for use with its pipeline of novel cancer vaccines.

• April 2023: Merck & Co., Inc. agreed to acquire Prometheus Biosciences for USD 200.00 per share in cash for a total equity value of approximately USD 10.8 billion. This agreement allows Prometheus Biosciences to maximize the potential for PRA023, a novel, late-stage candidate for ulcerative colitis, Crohn's disease, and other autoimmune conditions.
• March 2023: Takeda Pharmaceutical Company Limited received approval from the Japanese Ministry of Health, Labour, and Welfare for its Entyvio Pens (vedolizumab) maintenance therapy for moderate to severe ulcerative colitis.

• January 2023: Lupin Pharmaceuticals, a global player in drug discovery, launched the generic version of the combination drug in India following the patent expiry of Novartis' blockbuster heart drug Sacubitril and Valsartan, which will be marketed under two brand names, Valentas and Arnipin indicated for patients with Heart Failure (HF).
• January 2023: Glenmark Pharmaceuticals, a global pharmaceutical company, launched the sacubitril + valsartan prescription-only tablets in India for the treatment of HF, marketed under the brand name 'Sacu V.'

• June 2022: Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. announced strategic cooperation to develop, manufacture, and commercialize Liraglutide (including both indications of diabetes and obesity) in 17 countries in the Middle East and North Africa region (MENA) including the UAE.
• May 2022: The US FDA approved Eli Lilly and Company's Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

• October 2022: Zimbabwe approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
• October 2022: China handed a state-of-the-art pharmaceutical warehouse to the Zimbabwean government, which is expected to boost Zimbabwe's drug storage capacity and improve its health delivery system.

• October 2022: Alvotech and the JAMP Pharma Group (a Canadian pharmaceutical company) announced the expansion of their exclusive partnership to commercialize biosimilars (AVT16 & AVT33) developed and manufactured by Alvotech.
• May 2022: Biocon Biologics and Viatris (formerly Mylan) launched the cancer drug bevacizumab under the brand name Abevmy in Canada.
• April 2022: AMP Pharma Group, a Canadian-owned pharmaceutical company, announced the launch of SIMLANDI, a high-concentration, low-volume, citrate-free biosimilar to Humira (adalimumab), developed and manufactured by Alvotech.
• January 2022: Pfizer Canada entered a three-year partnership with the Canadian Race Relations Foundation (CRRF) to conduct a series of dialogues on health equity and concerns affecting racialized communities' access to health and mental health services.
• January 2022: Eli Lilly and Company entered into a research and collaboration partnership with Entos Pharmaceuticals in Canada. This deal will support the development of therapies for multiple neurological disorders.

• December 2022: Roche reported the launch of a drug for a rare autoimmune disorder, neuromyelitis optica spectrum disorder (NMOSD), in India by the end of 2023. This drug is focused on precision medicine.
• November 2022: BGI Genomics and the University of Pécs (UP) agreed to launch a joint laboratory in Hungary. The joint lab is to start official operations to accelerate the development of genomic sequencing and clinical diagnostic services while strengthening BGI Genomics and the UP's innovative precision medicine developments in the Central and Eastern European region.

• In August 2022, Glenmark Pharmaceuticals' arm has launched the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the United States market.
• In March 2022, Perrigo Company plc announced that it has received final approval from the US FDA for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).

• In November 2022, Glenmark Pharmaceuticals received approval from the US health regulator to market sodium phenylbutyrate tablets, used in treating urea cycle disorders, in America.
• In October 2022, Glenmark's United States-based unit launched generic Fingolimod capsules, used to treat multiple sclerosis, in the American market.